ArticleThe journal of nutrition, health & aging2009
Target population for clinical trials.
Article in The journal of nutrition, health & aging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Removal ofFrontiers in aging · 2021Article
- Does nutrition play a role in the prevention and management of sarcopenia?Clinical nutrition (Edinburgh, Scotland) · 2018Review
- Horse-racing effect and clinical trials in older persons.Frontiers in aging neuroscience · 2014Review
- Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials.The international journal of biochemistry & cell biology · 2013Review
- Sarcopenia: biomarkers and imaging (International Conference on Sarcopenia research).The journal of nutrition, health & aging · 2011Article
- Designing Phase II B trials in sarcopenia: the best target population.The journal of nutrition, health & aging · 2011Article
- Clinical trials on sarcopenia: methodological issues regarding phase 3 trials.Clinics in geriatric medicine · 2011Review
- Carla Task Force on Sarcopenia: propositions for clinical trials.The journal of nutrition, health & aging · 2009Article
- Frailty, what are we talking about? Implications for the daily clinical practice.Revista espanola de geriatria y gerontologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The target population for clinical trials aimed at sarcopenia depends on the goals of treatment and the expected natural history of sarcopenia. Based on a natural history where loss of muscle mass and/or quality leads to loss of strength, and eventually to reduced mobility and functional dependence, treatment goals can be defined for both preventive and therapeutic interventions. For example, a target population with low muscle mass and poor strength could be treated to prevent the onset of mobility disability, or a target population with low muscle mass and poor strength with mobility disability could be treated therapeutically to improve mobility. Eligibility for a trial should also be based on careful consideration of factors that affect 1) the ability to respond to treatment, 2) the safety of treatment, 3) expected prevalence and 4) feasibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.